Apetamin: Use of This Illegal Weight-Gain Product Can Bring Tragic Results

TUESDAY, May 2, 2023 (HealthDay News) -- U.S. regulators are urging Americans to avoid Apetamin, an illegal drug used for weight gain and figure enhancement. The substance, typically sold as a syrup, is manufactured overseas, is illegally imported, and is not approved by the U.S. Food and Drug Administration.
Apetamin contains the potent antihistamine cyproheptadine, which requires a physician's prescription in the United States. American consumers may find Apetamin online, on social media, or in some retail stores, but they should not use it, the FDA warned in an agency news release.
Among its dangerous side effects are potential overdose, sedation, cognitive impairment, dizziness, low blood pressure, disorientation and confusion, hallucinations, convulsions, and decreased breath and heart rates. It may lead to coma or death, the FDA said. The substance also decreases mental alertness, which may affect a person's ability to drive a car or operate machinery.
This strong antihistamine may be dangerously strengthened when taken with alcohol and other central nervous system depressants, such as hypnotics, sedatives, tranquilizers, and anti-anxiety medications, the FDA said.
Reports to the FDA Adverse Event Reporting System revealed young adults had taken Apetamin and experienced nervous system disorders, cardiac disorders, and liver injury, the agency said.
Related Posts
Atrial Fibrillation Tied to Worse Noncardiac Surgery Outcomes
TUESDAY, June 21, 2022 (HealthDay News) -- Preexisting atrial fibrillation (AF)...
Los datos israelíes sobre las dosis de refuerzo de la COVID se publican esta semana en una importante revista
MARTES, 14 de septiembre de 2021 (HealthDay News) -- Unos datos recientes de...
Aspirin Use Not Tied to Clinical Outcomes in Nonobstructive CAD
MONDAY, May 2, 2022 (HealthDay News) -- For individuals with nonobstructive...
Perder mucho peso podría ayudar a prevenir una COVID-19 grave
VIERNES, 31 de diciembre de 2021 (HealthDay News) -- La mayoría de las personas...
